Read by QxMD icon Read

Lymphocytic colitis

Mojtaba Shohan, Milad Sabzevary-Ghahfarokhi, Nader Bagheri, Hedayatollah Shirzad, Ghorbanali Rahimian, Amin Soltani, Mahdi Ghatreh-Samani, Fatemeh Deris, Kamran Tahmasbi, Elahe Shahverdi, Fereshteh Fathollahi
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory disorder of the large intestine histologically characterized by indistinct sustained inflammatory responses. Genetical susceptibility and environmental factors' effects play the roles in disease occurrence and it can be life threatening if remains untreated. It seems that intensification of inflammatory responses in this condition is not restricted to a specific cell line of T lymphocytes. Our aim was to determine the number of T helper 9 (Th9) cells in inflamed colonic biopsies of UC patients...
June 21, 2018: Immunological Investigations
Annika Reinhardt, Immo Prinz
γδ T cells, αβ T cells, and innate lymphoid cells (ILCs) are capable of producing interleukin (IL)-17A, IL-17F, and IL-22. Among these three families of lymphocytes, it is emerging that γδ T cells are, at least in rodents, the main source of these key pro-inflammatory cytokines. γδ T cells were implicated in multiple inflammatory and autoimmune diseases, including psoriasis, experimental autoimmune encephalomyelitis and uveitis, colitis, and rheumatoid arthritis. Recent findings pointed toward a central role of γδ T cells in the pathogenesis of spondyloarthritis (SpA), a group of inflammatory rheumatic diseases affecting the axial skeleton...
2018: Frontiers in Immunology
Ce Tang, Shigeru Kakuta, Kenji Shimizu, Motohiko Kadoki, Tomonori Kamiya, Tomoyuki Shimazu, Sachiko Kubo, Shinobu Saijo, Harumichi Ishigame, Susumu Nakae, Yoichiro Iwakura
The cytokines IL-17A and IL-17F have 50% amino-acid identity and bind the same receptor; however, their functional differences have remained obscure. Here we found that Il17f-/- mice resisted chemically induced colitis, but Il17a-/- mice did not, and that Il17f-/- CD45RBhi CD4+ T cells induced milder colitis in lymphocyte-deficient Rag2-/- mice, accompanied by an increase in intestinal regulatory T cells (Treg cells). Clostridium cluster XIVa in colonic microbiota capable of inducing Treg cells was increased in both Il17f-/- mice and mice given transfer Il17f-/- T cells, due to decreased expression of a group of antimicrobial proteins...
June 18, 2018: Nature Immunology
Yongjia Yan, Na Zhao, Xianghui He, Hao Guo, Zhixiang Zhang, Tong Liu
BACKGROUND: Interleukin-35 (IL-35) has recently been identified as an immunosuppressive cytokine that has been used as a potential therapy for chronic inflammatory and autoimmune diseases. However, there remains a paucity of data regarding its potential benefits after integration into mesenchymal stem cells (MSCs). METHODS: We used a dextran sulfate sodium (DSS)-induced colitis mice model and treated them with IL-35-MSCs, MSCs or saline. The body weight was recorded daily and inflammatory processes were determined...
June 12, 2018: Cytotherapy
Mahdis Monajemi, Yvonne C F Pang, Saelin Bjornson, Susan C Menzies, Nico van Rooijen, Laura M Sly
This study tested the hypothesis that Malt1 deficiency in macrophages contributes to dextran sodium sulfate (DSS)-induced intestinal inflammation in Malt1-deficient mice. In people, combined immunodeficiency caused by a homozygous mutation in the MALT1 gene is associated with increased susceptibility to bacterial infections and chronic inflammation, including severe inflammation along the gastrointestinal tract. The consequences of Malt1 deficiency have largely been attributed to its role in lymphocytes, but Malt1 is also expressed in macrophages, where it is activated downstream of TLR4 and dectin-1...
June 14, 2018: Journal of Leukocyte Biology
L Zhao, Y Yang, Y Zhang
Type II enteropathy-associated T-cell lymphoma (Type II EATL) is a rare peripheral T-cell lymphoma of the gastrointestinal tract. Here, we report a case of Type II EATL, in which the patient with repeated diarrhea was diagnosed as ulcerative colitis and amebic infection at the beginning, but her symptom had no improvement after therapy. The diagnosis of Type II EATL was confirmed by the repeated biopsies and immunohistochemistry. This case suggests that Type II EATL is difficult to diagnose due to lack of specific symptoms and endoscopic features...
June 2018: Nigerian Journal of Clinical Practice
Bing Wei, Ran Zhang, Jingbo Zhai, Junfeng Zhu, Fangli Yang, Dan Yue, Xiaoyi Liu, Changlong Lu, Xun Sun
Background: Ganoderma lucidum polysaccharides (GLP) has anti-inflammatory and immunomodulatory effects. Dysregulated immune responses are involved in the pathogenesis of dextran sulfate sodium (DSS)-induced colitis. The aim of this study was to assess the therapeutic potential of GLP to alleviate DSS-induced colitis. Methods: The mice were administered with GLP by intragastric gavage daily for two weeks prior to the DSS treatment. Mice were orally administered with 2...
2018: Journal of Immunology Research
Javier Roig, Maria L Saiz, Alicia Galiano, Maria Trelis, Fernando Cantalapiedra, Carlos Monteagudo, Elisa Giner, Rosa M Giner, M C Recio, Dolores Bernal, Francisco Sánchez-Madrid, Antonio Marcilla
The complexity of the pathogenesis of inflammatory bowel disease (ulcerative colitis and Crohn's disease) has led to the quest of empirically drug therapies, combining immunosuppressant agents, biological therapy and modulators of the microbiota. Helminth parasites have been proposed as an alternative treatment of these diseases based on the hygiene hypothesis, but ethical and medical problems arise. Recent reports have proved the utility of parasite materials, mainly excretory/secretory products as therapeutic agents...
2018: Frontiers in Microbiology
Tomoya Fukui, Yuriko Okuma, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masato Katagiri, Hisashi Mitsufuji, Masaru Kubota, Yasuhiro Hiyoshi, Mikiko Ishihara, Masashi Kasajima, Jiichiro Sasaki, Katsuhiko Naoki
BACKGROUND: The immune checkpoint inhibitor nivolumab is entering routine oncologic practice. We investigated the safety and efficacy of nivolumab in the real world and alternative predictive factors for survival in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We performed a prospective observational study to evaluate the activity of nivolumab treatment for chemotherapy-refractory NSCLC. Patients were treated with nivolumab once every 2 weeks, and the efficacy was assessed every 8 ± 2 weeks...
May 5, 2018: Clinical Lung Cancer
Rocco Spagnuolo, Vincenzo Dattilo, Lucia D'Antona, Cristina Cosco, Rossana Tallerico, Valeria Ventura, Francesco Conforti, Caterina Camastra, Rosellina M Mancina, Giada Catalogna, Vincenzo Cosco, Rodolfo Iuliano, Ennio Carbone, Nicola Perrotti, Rosario Amato, Patrizia Doldo
Background: Inflammatory bowel disease (IBD) is due to the interaction of genetic and environmental factors that trigger an unbalanced immune response ultimately resulting in the peculiar inflammatory reaction. Experimental models of IBD point to a role of T-cell-derived cytokines (Th17) and to SGK1 as mediator of the Th17 switch. We hypothesize that SGK1, a salt inducible kinase, directs lymphocytic behavior and tissue damage. Methods: Eleven controls and 32 ulcerative colitis (UC) patients were randomized according to endoscopic Mayo score...
May 18, 2018: Inflammatory Bowel Diseases
Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake, Simon P L Travis
Background and Aims: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods: Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab in ulcerative colitis [UC; GEMINI 1] and Crohn's disease [CD; GEMINI 2], and a long-term safety study [UC and CD] were pooled...
May 17, 2018: Journal of Crohn's & Colitis
Ecaterina Ileana Dumbrava, Veronica Smith, Rasha Alfattal, Adel K El-Naggar, Marta Penas-Prado, Apostolia M Tsimberidou
Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response...
May 21, 2018: Journal of Immunotherapy
Xiaoxi Xu, Yong Wang, Baoren Zhang, Xu Lan, Shanzheng Lu, Peng Sun, Xiang Li, Ganggang Shi, Yiming Zhao, Hongqiu Han, Caigan Du, Hao Wang
BACKGROUND: Endometrial regenerative cells (ERCs), a novel type of mesenchymal-like stem cell derived from menstrual blood, have been recently evaluated as an attractive candidate source in ulcerative colitis (UC); however, the mechanism is not fully understood. The present study was designed to investigate the effects of ERCs, especially on B-cell responses in UC. METHODS: In this study, colitis was induced by administering 3% dextran sodium sulfate (DSS) via free drinking water for 7 days to BALB/c mice...
May 22, 2018: Stem Cell Research & Therapy
Mark G Ward, Miles P Sparrow, Xavier Roblin
The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn's disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary loss of response to vedolizumab do occur, as is observed with the use of anti-tumour necrosis factor (TNF) therapy. Further, in a proportion, onset of efficacy may be relatively slow. A large body of data support an exposure-response relationship with anti-TNF drug levels, which has led to therapeutic drug monitoring becoming incorporated into everyday clinical management...
2018: Therapeutic Advances in Gastroenterology
Jintao Li, Ji Zhang, Hongxia Guo, Shimin Yang, Weiping Fan, Nan Ye, Zhiqiang Tian, Tiantian Yu, Guoping Ai, Zigang Shen, Haiyang He, Ping Yan, Hui Lin, Xue Luo, Hongli Li, Yuzhang Wu
Inflammatory bowel disease (IBD) is associated with dysregulation of both innate and adaptive immune response in the intestine. MicroRNA (miR)-155 is frequently expressed and functions in many immune cell types. Besides its function in adaptive immunity, miR-155 is a key regulator of the innate immune response in macrophages, dendritic cells, and even in epithelia cells. Although the roles of miR-155 within T and B lymphocytes in colitis have been reported, its function in innate immune cells has not been thoroughly examined...
2018: Frontiers in Immunology
Christopher Pleyer, Adrian Wiestner, Clare Sun
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interactions, modulating the T-cell compartment, and altering the cytokine milieu. Ibrutinib also partially restores T-cell and myeloid defects associated with CLL. In contrast, immune-related adverse effects, including pneumonitis, colitis, hepatotoxicity, and infections are of particular concern with idelalisib...
May 15, 2018: Leukemia & Lymphoma
Bruce Weder, Mahdi Mozaffari, Luc Biedermann, Céline Mamie, Anja Moncsek, Lichun Wang, Stephen H Clarke, Gerhard Rogler, Bradford L McRae, Candace L Graff, Pedro A Ruiz, Martin Hausmann
INTRODUCTION: In inflammatory bowel disease (IBD), inflammation is sustained by an exaggerated response of lymphocytes. This results from enhanced expression of anti-apoptotic BCL-2 and BCL-XL associated with a diminished turnover. Azathioprine (AZA) directly targets BCL-2 family-mediated apoptosis. We investigated whether the BCL-2 family expression pattern could be used to predict treatment response to AZA and determined whether BCL-2 inhibitor A-1211212 effectively diminishes lymphocytes and ameliorates inflammation in a model of colitis...
May 10, 2018: Clinical and Experimental Immunology
Daisuke Saito, Mari Hayashida, Taro Sato, Shintaro Minowa, Osamu Ikezaki, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Tadakazu Hisamatsu
Background/Aims: Mesalazine is an effective drug for treating ulcerative colitis (UC), but causes allergic symptoms in a few cases. Therefore, the objective of this study was to evaluate the usefulness of the drug-induced lymphocyte stimulation test (DLST) for the diagnosis of mesalazine allergy. Methods: Patients with UC treated with mesalazine with or without a history of associated adverse events (AEs) were enrolled at Kyorin University Hospital from July 2016 to April 2017...
April 2018: Intestinal Research
Michelle Moore, Helen G Coleman, Patrick B Allen, Maurice B Loughrey
AIM: We report clinicopathological experience of microscopic colitis in a population-based case series in Northern Ireland, over a nine year period. METHOD: The pathology laboratory information system within a large teaching centre serving two healthcare trusts was interrogated for cases coded between 2008 and 2016 as collagenous colitis (CC) or lymphocytic colitis (LC). Demographic, clinical and follow up information was collected from healthcare records. RESULTS: A total of 326 new diagnoses of MC were identified, an average annual incidence of 6...
May 9, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Ana M Dias, Alexandra Correia, Márcia S Pereira, Catarina R Almeida, Inês Alves, Vanda Pinto, Telmo A Catarino, Nuno Mendes, Magdalena Leander, M Teresa Oliva-Teles, Luís Maia, Cristina Delerue-Matos, Naoyuki Taniguchi, Margarida Lima, Isabel Pedroto, Ricardo Marcos-Pinto, Paula Lago, Celso A Reis, Manuel Vilanova, Salomé S Pinho
Mucosal T lymphocytes from patients with ulcerative colitis (UC) were previously shown to display a deficiency in branched N-glycosylation associated with disease severity. However, whether this glycosylation pathway shapes the course of the T cell response constituting a targeted-specific mechanism in UC remains largely unknown. In this study, we demonstrated that metabolic supplementation of ex vivo mucosal T cells from patients with active UC with N -acetylglucosamine (GlcNAc) resulted in enhancement of branched N-glycosylation in the T cell receptor (TCR), leading to suppression of T cell growth, inhibition of the T helper 1 (Th1)/Th17 immune response, and controlled T cell activity...
May 15, 2018: Proceedings of the National Academy of Sciences of the United States of America
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"